HRMY - Why Is Sleep Disorder Related Harmony Biosciences Stock Trading Lower Today? | Benzinga
Harmony Biosciences Holdings Inc (NASDAQ: HRMY) announced topline results from the INTUNE Phase 3 study of pitolisant in patients with idiopathic hypersomnia (IH).
Idiopathic hypersomnia is a central disorder of hypersomnolence, primarily characterized by the irresistible need to sleep and waking up non-refreshed despite the prolonged sleep duration.
Approximately 83% of patients who completed the 8-week open-label treatment period with pitolisant were responders and experienced a robust clinical response, with an average ...